Application of nutrigenomic concepts to Type 2 diabetes mellitus

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 17, Issue 2, 2007, Pages 89-103

  Kaput, Jim ^a,b,c   Noble, Janelle ^b,d   Hatipoglu, Betul ^a   Kohrs, Kari ^a   Dawson, Kevin ^b   Bartholomew, Amelia ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NuGO ^*  (Netherlands)

^d CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

Nutrigenomics; Type 2 diabetes mellitus

Indexed keywords

AGED; CALORIC INTAKE; CHRONIC DISEASE; DIET; DIET THERAPY; EATING; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOMICS; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; NUTRITIONAL REQUIREMENT; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

AGED; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; DIET; EATING; ENERGY INTAKE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; MALE; MIDDLE AGED; NUTRITION PHYSIOLOGY; NUTRITIONAL REQUIREMENTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 33846990448     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2006.11.006     Document Type: Review

References (151)

1. Kaput J., and Rodriguez R.L. Nutritional genomics: the next frontier in the postgenomic era. Physiol Genomics 16 (2004) 166-177
2. Ordovas J.M. The quest for cardiovascular health in the genomic era: nutrigenetics and plasma lipoproteins. Proc Nutr Soc 63 (2004) 145-152
3. Corella D., and Ordovas J.M. The metabolic syndrome: a crossroad for genotype-phenotype associations in atherosclerosis. Curr Atheroscler Rep 6 (2004) 186-196
4. Vincent S., Planells R., Defoort C., Bernard M.C., Gerber M., Prudhomme J., et al. Genetic polymorphisms and lipoprotein responses to diets. Proc Nutr Soc 61 (2002) 427-434
5. Finnell R.H., Shaw G.M., Lammer E.J., and Volcik K.A. Does prenatal screening for 5,10-methylenetetrahydrofolate reductase (MTHFR) mutations in high-risk neural tube defect pregnancies make sense?. Genet Test 6 (2002) 47-52
6. Corella D., and Ordovas J.M. Single nucleotide polymorphisms that influence lipid metabolism: interaction with dietary factors. Annu Rev Nutr 25 (2005) 341-390
7. Williams, R. Biochemical individuality. New Canaan, Connecticut: John Wiley and Sons (1956), Keats Publishing Company (1998); 1956.
8. Curtis J., and Wilson C. Preventing type 2 diabetes mellitus. J Am Board Fam Pract 18 (2005) 37-43
9. Pirola L., Johnston A.M., and Van Obberghen E. Modulation of insulin action. Diabetologia 47 (2004) 170-184
10. Patti M.E. Gene expression in humans with diabetes and prediabetes: what have we learned about diabetes pathophysiology?. Curr Opin Clin Nutr Metab Care 7 (2004) 383-390
11. Parikh H., and Groop L. Candidate genes for type 2 diabetes. Rev Endocr Metab Disord 5 (2004) 151-176
12. Laakso M. Gene variants, insulin resistance, and dyslipidaemia. Curr Opin Lipidol 15 (2004) 115-120
13. Steinmetz A. Treatment of diabetic dyslipoproteinemia. Exp Clin Endocrinol Diabetes 111 (2003) 239-245
14. Hanson R.L., and Knowler W.C. Quantitative trait linkage studies of diabetes-related traits. Curr Diab Rep 3 (2003) 176-183
15. Hansen L. Candidate genes and late-onset type 2 diabetes mellitus. Susceptibility genes or common polymorphisms?. Dan Med Bull 50 (2003) 320-346
16. Florez J.C., Hirschhorn J., and Altshuler D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet 4 (2003) 257-291
17. McCarthy M.I., and Froguel P. Genetic approaches to the molecular understanding of type 2 diabetes. Am J Physiol Endocrinol Metab 283 (2002) E217-E225
18. Freeman H., and Cox R.D. Type-2 diabetes: a cocktail of genetic discovery. Hum Mol Genet 15 Suppl. 2 (2006) R202-R209
19. EndocrineWeb, Accessed 31 January 2006.
20. Nathan D.M. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347 (2002) 1342-1349
21. Ahmann A.J., and Riddle M.C. Current oral agents for type 2 diabetes. Many options, but which to choose when?. Postgrad Med 111 (2002) 32-34 [37-40, 43-6]
22. Cordain L., Eades M.R., and Eades M.D. Hyperinsulinemic diseases of civilization: more than just Syndrome X. Comp Biochem Physiol A Mol Integr Physiol 136 (2003) 95-112
23. McMillen I.C., and Robinson J.S. Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiol Rev 85 (2005) 571-633
24. Koro C.E., Bowlin S.J., Bourgeois N., and Fedder D.O. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 27 (2004) 17-20
25. Kwon G., Marshall C.A., Pappan K.L., Remedi M.S., and McDaniel M.L. Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets. Diabetes 53 Suppl. 3 (2004) S225-S232
26. Wolford J.K., and Vozarova de Courten B. Genetic basis of type 2 diabetes mellitus: implications for therapy. Treat Endocrinol 3 (2004) 257-267
27. Flint J., Valdar W., Shifman S., and Mott R. Strategies for mapping and cloning quantitative trait genes in rodents. Nat Rev Genet 6 (2005) 271-286
28. Kaput J., Klein K.G., Reyes E.J., Kibbe W.A., Cooney C.A., Jovanovic B., et al. Identification of genes contributing to the obese yellow Avy phenotype: caloric restriction, genotype, diet × genotype interactions. Physiol Genomics 18 (2004) 316-324
29. Kaput J. Diet-disease gene interactions. Nutrition 20 (2004) 26-31
30. Kaput J., Swartz D., Paisley E., Mangian H., Daniel W.L., and Visek W.J. Diet-disease interactions at the molecular level: an experimental paradigm. J Nutr 124 (1994) 1296S-1305S
31. Irwin M. Effects of sleep and sleep loss on immunity and cytokines. Brain Behav Immun 16 (2002) 503-512
32. Redwine L., Hauger R.L., Gillin J.C., and Irwin M. Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans. J Clin Endocrinol Metab 85 (2000) 3597-3603
33. Prabhakar N.R., and Peng Y.J. Peripheral chemoreceptors in health and disease. J Appl Physiol 96 (2004) 359-366
34. Serhan C.N., Clish C.B., Brannon J., Colgan S.P., Chiang N., and Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-non-steroidal antiinflammatory drugs and transcellular processing. J Exp Med 192 (2000) 1197-1204
35. Tomita M., Irwin K.I., Xie Z.J., and Santoro T.J. Tea pigments inhibit the production of Type 1 (T(H1)) and Type 2 (T(H2)) helper T cell cytokines in CD4(+) T cells. Phytother Res 16 (2002) 36-42
36. Nieman D.C., Davis J.M., Henson D.A., Walberg-Rankin J., Shute M., Dumke C.L., et al. Carbohydrate ingestion influences skeletal muscle cytokine mRNA and plasma cytokine levels after a 3-h run. J Appl Physiol 94 (2003) 1917-1925
37. Nieman D.C., Davis J.M., Brown V.A., Henson D.A., Dumke C.L., Utter A.C., et al. Influence of carbohydrate ingestion on immune changes after 2 h of intensive resistance training. J Appl Physiol 96 (2004) 1292-1298
38. Nieman D.C., Dumke C.I., Henson D.A., McAnulty S.R., McAnulty L.S., Lind R.H., et al. Immune and oxidative changes during and following the Western States Endurance Run. Int J Sports Med 24 (2003) 541-547
39. Chakravarthy M.V., and Booth F.W. Eating, exercise, and "thrifty" genotypes: connecting the dots toward an evolutionary understanding of modern chronic diseases. J Appl Physiol 96 (2004) 3-10
40. Gleeson M., Nieman D.C., and Pedersen B.K. Exercise, nutrition and immune function. J Sports Sci 22 (2004) 115-125
41. Irwin M., Clark C., Kennedy B., Gillin J.C., and Ziegler M. Nocturnal catecholamines and immune function in insomniacs, depressed patients, and control subjects. Brain Behav Immun 17 (2003) 365-372
42. Pandya R.J., Solomon G., Kinner A., and Balmes J.R. Diesel exhaust and asthma: hypotheses and molecular mechanisms of action. Environ Health Perspect 110 Suppl. 1 (2002) 103-112
43. Albrecht U., and Eichele G. The mammalian circadian clock. Curr Opin Genet Dev 13 (2003) 271-277
44. Seeley R.J., Drazen D.L., and Clegg D.J. The critical role of the melanocortin system in the control of energy balance. Annu Rev Nutr 24 (2004) 133-149
45. Sing C.F., Stengard J.H., and Kardia S.L. Genes, environment, and cardiovascular disease. Arterioscler Thromb Vasc Biol 23 (2003) 1190-1196
46. Costacou T., and Mayer-Davis E.J. Nutrition and prevention of Type 2 diabetes. Annu Rev Nutr 27 (2003) 147-170
47. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
48. He L., and Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5 (2004) 522-531
49. Nakahara K., and Carthew R.W. Expanding roles for miRNAs and siRNAs in cell regulation. Curr Opin Cell Biol 16 (2004) 127-133
50. Scherr M., and Eder M. RNAi in functional genomics. Curr Opin Mol Ther 6 (2004) 129-135
51. Goto A., Blandin S., Royet J., Reichhart J.M., and Levashina E.A. Silencing of Toll pathway components by direct injection of double-stranded RNA into Drosophila adult flies. Nucleic Acids Res 31 (2003) 6619-6623
52. Santaniemi M., Ukkola O., and Kesaniemi Y.A. Tyrosine phosphatase 1B and leptin receptor genes and their interaction in Type 2 diabetes. J Intern Med 256 (2004) 48-55
53. Caporaso N.E. Why have we failed to find the low penetrance genetic constituents of common cancers?. Cancer Epidemiol Biomarkers Prev 11 (2002) 1544-1549
54. Hartman J.L., Garvik B., and Hartwell L. Principles for the buffering of genetic variation. Science 291 (2001) 1001-1004
55. Tishkoff S.A., and Kidd K.K. Implications of biogeography of human populations for 'race' and medicine. Nat Genet 36 Suppl. 1 (2004) S21-S27
56. Jorde L.B., and Wooding S.P. Genetic variation, classification and 'race'. Nat Genet 36 Suppl. 1 (2004) S28-S33
57. Helgadottir A., Manolescu A., Helgason A., Thorleifsson G., Thorsteinsdottir U., Gudbjartsson D.F., et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 38 (2006) 68-74
58. Delaval K., and Feil R. Epigenetic regulation of mammalian genomic imprinting. Curr Opin Genet Dev 14 (2004) 188-195
59. Sneider T.W., Teague W.M., and Rogachevsky L.M. S-adenosylmethionine: DNA-cytosine 5-methyltransferase from a Novikoff rat hepatoma cell line. Nucleic Acids Res 2 (1975) 1685-1700
60. Mason J.B. Biomarkers of nutrient exposure and status in one-carbon (methyl) metabolism. J Nutr 133 Suppl. 3 (2003) 941S-947S
61. Stover P.J., and Garza C. Bringing individuality to public health recommendations. J Nutr 132 (2002) 2476S-2480S
62. Blander G., and Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 73 (2004) 417-435
63. Jiang Y.H., Bressler J., and Beaudet A.L. Epigenetics and human disease. Annu Rev Genomics Hum Genet 5 (2004) 479-510
64. Young V.R., and Scrimshaw N.S. Genetic and biological variability in human nutrient requirements. Am J Clin Nutr 32 (1979) 486-500
65. Ottman R. Gene-environment interaction: definitions and study designs. Prev Med 25 (1996) 764-770
66. Memisoglu A., Hu F.B., Hankinson S.E., Manson J.E., De Vivo I., Willett W.C., et al. Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet 12 (2003) 2923-2929
67. Mantzoros C.S., Williams C.J., Manson J.E., Meigs J.B., and Hu F.B. Adherence to the Mediterranean dietary pattern is positively associated with plasma adiponectin concentrations in diabetic women. Am J Clin Nutr 84 (2006) 328-335
68. Cardillo S., Seshadri P., and Iqbal N. The effects of a low-carbohydrate versus low-fat diet on adipocytokines in severely obese adults: three-year follow-up of a randomized trial. Eur Rev Med Pharmacol Sci 10 (2006) 99-106
69. Butte N.F., Comuzzie A.G., Cai G., Cole S.A., Mehta N.R., and Bacino C.A. Genetic and environmental factors influencing fasting serum adiponectin in Hispanic children. J Clin Endocrinol Metab 90 (2005) 4170-4176
70. Eisenach J.H., Schroeder D.R., Pike T.L., Johnson C.P., Schrage W.G., Snyder E.M., et al. Dietary sodium restriction and beta2-adrenergic receptor polymorphism modulate cardiovascular function in humans. J Physiol 574 (2006) 955-965
71. Loos R.J., Rankinen T., Rice T., Rao D.C., Leon A.S., Skinner J.S., et al. Two ethnic-specific polymorphisms in the human Agouti-related protein gene are associated with macronutrient intake. Am J Clin Nutr 82 (2005) 1097-1101
72. Tozawa Y. G protein beta3 subunit variant: tendency of increasing susceptibility to hypertension in Japanese. Blood Press 10 (2001) 131-134
73. Bos G., Dekker J.M., Feskens E.J., Ocke M.C., Nijpels G., Stehouwer C.D., et al. Interactions of dietary fat intake and the hepatic lipase -480C → T polymorphism in determining hepatic lipase activity: the Hoorn Study. Am J Clin Nutr 81 (2005) 911-915
74. Dos Santos C., Fallin D., Le Stunff C., LeFur S., and Bougneres P. INS VNTR is a QTL for the insulin response to oral glucose in obese children. Physiol Genomics 16 (2004) 309-313
75. Sierksma A., van der Gaag M.S., van Tol A., James R.W., and Hendriks H.F. Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers. Alcohol Clin Exp Res 26 (2002) 1430-1435
76. Cha M.H., Shin H.D., Kim K.S., Lee B.H., and Yoon Y. The effects of uncoupling protein 3 haplotypes on obesity phenotypes and very low-energy diet-induced changes among overweight Korean female subjects. Metabolism 55 (2006) 578-586
77. Ukkola O., Tremblay A., Sun G., Chagnon Y.C., and Bouchard C. Genetic variation at the uncoupling protein 1, 2 and 3 loci and the response to long-term overfeeding. Eur J Clin Nutr 55 (2001) 1008-1015
78. Roche H.M., Phillips C., and Gibney M.J. The metabolic syndrome: the crossroads of diet and genetics. Proc Nutr Soc 64 (2005) 371-377
79. Roche H.M. Fatty acids and the metabolic syndrome. Proc Nutr Soc 64 (2005) 23-29
80. Chambrier C., Bastard J.P., Rieusset J., Chevillotte E., Bonnefont-Rousselot D., Therond P., et al. Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor gamma. Obes Res 10 (2002) 518-525
81. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., and Evans R.M. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83 (1995) 803-812
82. Nosjean O., and Boutin J.A. Natural ligands of PPARgamma: are prostaglandin J(2) derivatives really playing the part?. Cell Signal 14 (2002) 573-583
83. Kaput J., Ordovas J.M., Ferguson L., van Ommen B., Rodriguez R.L., and Allen L. The case for strategic international alliances to harness nutritional genomics for public and personal health. Br J Nutr 94 (2005) 623-632
84. Kaput J. An introduction and overview of nutritional genomics: application to Type 2 diabetes and international nutrigenomics. In: Kaput J., and Rodriguez R.L. (Eds). Nutritional genomics: discovering the path to personalized nutrition (2006), John Wiley and Sons, Hobeken, NJ 1-36
85. Hansen L., and Pedersen O. Genetics of Type 2 diabetes mellitus: status and perspectives. Diabetes Obes Metab 7 (2005) 122-135
86. Barroso I., Luan J., Middelberg R.P., Harding A.H., Franks P.W., Jakes R.W., et al. Candidate gene association study in Type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action. PLoS Biol 1 (2003) E20
87. Hani E.H., Clement K., Velho G., Vionnet N., Hager J., Philippi A., et al. Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes 46 (1997) 688-694
88. Lucarini N., Antonacci E., Bottini N., Borgiani P., Faggioni G., and Gloria-Bottini F. Phosphotyrosine-protein-phosphatase and diabetic disorders. Further studies on the relationship between low molecular weight acid phosphatase genotype and degree of glycemic control. Dis Markers 14 (1998) 121-125
89. Bottini E., and Gloria-Bottini F. Adenosine deaminase and body mass index in non-insulin-dependent diabetes mellitus. Metabolism 48 (1999) 949-951
90. Gonzalez Sanchez J.L., Proenza A.M., Martinez Larrad M.T., Ramis J.M., Fernandez Perez C., Palou A., et al. The glutamine 27 glutamic acid polymorphism of the beta2-adrenoceptor gene is associated with abdominal obesity and greater risk of impaired glucose tolerance in men but not in women: a population-based study in Spain. Clin Endocrinol (Oxf) 59 (2003) 476-481
91. Ellsworth D.L., Coady S.A., Chen W., Srinivasan S.R., Elkasabany A., Gustat J., et al. Influence of the beta2-adrenergic receptor Arg16Gly polymorphism on longitudinal changes in obesity from childhood through young adulthood in a biracial cohort: the Bogalusa Heart Study. Int J Obes Relat Metab Disord 26 (2002) 928-937
92. Barroso I. Genetics of Type 2 diabetes. Diabet Med 22 (2005) 517-535
93. Marks D.L., Boucher N., Lanouette C.M., Perusse L., Brookhart G., Comuzzie A.G., et al. Ala67Thr polymorphism in the Agouti-related peptide gene is associated with inherited leanness in humans. Am J Med Genet A 126 (2004) 267-271
94. Fumeron F., Aubert R., Siddiq A., Betoulle D., Pean F., Hadjadj S., et al. Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period: the epidemiologic data on the insulin resistance syndrome prospective study. Diabetes 53 (2004) 1150-1157
95. Gu H.F., Abulaiti A., Ostenson C.G., Humphreys K., Wahlestedt C., Brookes A.J., et al. Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1) gene are associated with Type 2 diabetes in Swedish Caucasians. Diabetes 53 Suppl. 1 (2004) S31-S35
96. Leipold H., Knofler M., Gruber C., Haslinger P., Bancher-Todesca D., and Worda C. Calpain-10 haplotype combination and association with gestational diabetes mellitus. Obstet Gynecol 103 (2004) 1235-1240
97. Carlsson E., Fredriksson J., Groop L., and Ridderstrale M. Variation in the calpain-10 gene is associated with elevated triglyceride levels and reduced adipose tissue messenger ribonucleic acid expression in obese Swedish subjects. J Clin Endocrinol Metab 89 (2004) 3601-3605
98. Hamaguchi K., Terao H., Kusuda Y., Yamashita T., Hazoury Bahles J.A., Cruz L.M., et al. The PC-1 Q121 allele is exceptionally prevalent in the Dominican Republic and is associated with Type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 1359-1364
99. Weiss E.P., Brown M.D., Shuldiner A.R., and Hagberg J.M. Fatty acid binding protein-2 gene variants and insulin resistance: gene and gene-environment interaction effects. Physiol Genomics 10 (2002) 145-157
100. Gertow K., Bellanda M., Eriksson P., Boquist S., Hamsten A., Sunnerhagen M., et al. Genetic and structural evaluation of fatty acid transport protein-4 in relation to markers of the insulin resistance syndrome. J Clin Endocrinol Metab 89 (2004) 392-399
101. Carlsson E., Groop L., and Ridderstrale M. Role of the FOXC2 -512C > T polymorphism in Type 2 diabetes: possible association with the dysmetabolic syndrome. Int J Obes Relat Metab Disord 29 (2005) 268-274
102. Holmkvist J., Almgren P., Parikh H., Zucchelli M., Kere J., Groop L., et al. Haplotype construction of the FRDA gene and evaluation of its role in Type II diabetes. Eur J Hum Genet 13 (2005) 849-855
103. Hirai M., Suzuki S., Hinokio Y., Hirai A., Chiba M., Akai H., et al. Variations in vitamin D-binding protein (group-specific component protein) are associated with fasting plasma insulin levels in Japanese with normal glucose tolerance. J Clin Endocrinol Metab 85 (2000) 1951-1953
104. Marz W., Nauck M., Hoffmann M.M., Nagel D., Boehm B.O., Koenig W., et al. G(-30)A polymorphism in the pancreatic promoter of the glucokinase gene associated with angiographic coronary artery disease and Type 2 diabetes mellitus. Circulation 109 (2004) 2844-2849
105. Gidh-Jain M., Takeda J., Xu L.Z., Lange A.J., Vionnet N., Stoffel M., et al. Glucokinase mutations associated with non-insulin-dependent (Type 2) diabetes mellitus have decreased enzymatic activity: implications for structure/function relationships. Proc Natl Acad Sci USA 90 (1993) 1932-1936
106. Takeda J., Gidh-Jain M., Xu L.Z., Froguel P., Velho G., Vaxillaire M., et al. Structure/function studies of human beta-cell glucokinase. Enzymatic properties of a sequence polymorphism, mutations associated with diabetes, and other site-directed mutants. J Biol Chem 268 (1993) 15200-15204
107. Zhang H., Jia Y., Cooper J.J., Hale T., Zhang Z., and Elbein S.C. Common variants in glutamine:fructose-6-phosphate amidotransferase 2 (GFPT2) gene are associated with Type 2 diabetes, diabetic nephropathy, and increased GFPT2 mRNA levels. J Clin Endocrinol Metab 89 (2004) 748-755
108. Miraglia del Giudice E., Santoro N., Cirillo G., Raimondo P., Grandone A., D'Aniello A., et al. Molecular screening of the ghrelin gene in Italian obese children: the Leu72Met variant is associated with an earlier onset of obesity. Int J Obes Relat Metab Disord 28 (2004) 447-450
109. Korbonits M., Gueorguiev M., O'Grady E., Lecoeur C., Swan D.C., Mein C.A., et al. A variation in the ghrelin gene increases weight and decreases insulin secretion in tall, obese children. J Clin Endocrinol Metab 87 (2002) 4005-4008
110. Poston W.S., Haddock C.K., Spertus J., Catanese D.M., Pavlik V.N., Hyman D.J., et al. Physical activity does not mitigate G-protein-related genetic risk for obesity in individuals of African descent. Eat Weight Disord 7 (2002) 68-71
111. Boutin P., Gresh L., Cisse A., Hara M., Bell G., Babu S., et al. Missense mutation Gly574Ser in the transcription factor HNF-1alpha is a marker of atypical diabetes mellitus in African-American children. Diabetologia 42 (1999) 380-381
112. Gasa R., Gomis R., Casamitjana R., Rivera F., and Novials A. Glucose regulation of islet amyloid polypeptide gene expression in rat pancreatic islets. Am J Physiol 272 (1997) E543-E549
113. Ritzel R.A., and Butler P.C. Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes 52 (2003) 1701-1708
114. Arends N., Johnston L., Hokken-Koelega A., van Duijn C., de Ridder M., Savage M., et al. Polymorphism in the IGF-I gene: clinical relevance for short children born small for gestational age (SGA). J Clin Endocrinol Metab 87 (2002) 2720
115. Mohlig M., Boeing H., Spranger J., Osterhoff M., Kroke A., Fisher E., et al. Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting Type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 1885-1890
116. McKenzie J.A., Weiss E.P., Ghiu I.A., Kulaputana O., Phares D.A., Ferrell R.E., et al. Influence of the interleukin-6 -174 G/C gene polymorphism on exercise training-induced changes in glucose tolerance indexes. J Appl Physiol 97 (2004) 1338-1342
117. Kubaszek A., Pihlajamaki J., Komarovski V., Lindi V., Lindstrom J., Eriksson J., et al. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to Type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 52 (2003) 1872-1876
118. Hassan M.I., Aschner Y., Manning C.H., Xu J., and Aschner J.L. Racial differences in selected cytokine allelic and genotypic frequencies among healthy, pregnant women in North Carolina. Cytokine 21 (2003) 10-16
119. Sanchez-Corona J., Flores-Martinez S.E., Machorro-Lazo M.V., Galaviz-Hernandez C., Moran-Moguel M.C., Perea F.J., et al. Polymorphisms in candidate genes for Type 2 diabetes mellitus in a Mexican population with metabolic syndrome findings. Diabetes Res Clin Pract 63 (2004) 47-55
120. Undlien D.E., Bennett S.T., Todd J.A., Akselsen H.E., Ikaheimo I., Reijonen H., et al. Insulin gene region-encoded susceptibility to IDDM maps upstream of the insulin gene. Diabetes 44 (1995) 620-625
121. Matejkova-Behanova M., Vankova M., Hill M., Kucera P., Cinek O., Andel M., et al. Polymorphism of INS VNTR is associated with glutamic acid decarboxylase antibodies and postprandial C-peptide in patients with onset of diabetes after 35 years of age. Physiol Res 53 (2004) 187-190
122. Heude B., Dubois S., Charles M.A., Deweirder M., Dina C., Borys J.M., et al. VNTR polymorphism of the insulin gene and childhood overweight in a general population. Obes Res 12 (2004) 499-504
123. Macfarlane W.M., Frayling T.M., Ellard S., Evans J.C., Allen L.I., Bulman M.P., et al. Missense mutations in the insulin promoter factor-1 gene predispose to Type 2 diabetes. J Clin Invest 104 (1999) R33-R39
124. Hani E.H., Stoffers D.A., Chevre J.C., Durand E., Stanojevic V., and Dina C. Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset Type 2 diabetes mellitus. J Clin Invest 104 (1999) R41-R48
125. Yamada K., Yuan X., Ishiyama S., Ichikawa F., Kohno S., Shoji S., et al. Identification of a single nucleotide insertion polymorphism in the upstream region of the insulin promoter factor-1 gene: an association study with diabetes mellitus. Diabetologia 41 (1998) 603-605
126. Mammarella S., Romano F., Di Valerio A., Creati B., Esposito D.L., Palmirotta R., et al. Interaction between the G1057D variant of IRS-2 and overweight in the pathogenesis of Type 2 diabetes. Hum Mol Genet 9 (2000) 2517-2521
127. Nielsen E.M., Hansen L., Carstensen B., Echwald S.M., Drivsholm T., Glumer C., et al. The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of Type 2 diabetes. Diabetes 52 (2003) 573-577
128. Todorova B., Kubaszek A., Pihlajamaki J., Lindstrom J., Eriksson J., Valle T.T., et al. The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to Type 2 diabetes mellitus: the Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 89 (2004) 2019-2023
129. Yabu Y., Noma K., Nakatani K., Nishioka J., Suematsu M., Katsuki A., et al. C-514T polymorphism in hepatic lipase gene promoter is associated with elevated triglyceride levels and decreasing insulin sensitivity in non-diabetic Japanese subjects. Int J Mol Med 16 (2005) 421-425
130. Ma Y.Q., Thomas G.N., Ng M.C., Critchley J.A., Chan J.C., and Tomlinson B. The lipoprotein lipase gene HindIII polymorphism is associated with lipid levels in early-onset Type 2 diabetic patients. Metabolism 52 (2003) 338-343
131. Malecki M.T., Jhala U.S., Antonellis A., Fields L., Doria A., Orban T., et al. Mutations in NEUROD1 are associated with the development of Type 2 diabetes mellitus. Nat Genet 23 (1999) 323-328
132. Ruiz-Quezada S., Vazquez-Del Mercado M., Parra-Rojas I., Rangel-Villalobos H., Best-Aguilera C., Sanchez-Orozco L.V., et al. Genotype and allele frequency of PAI-1 promoter polymorphism in healthy subjects from the west of Mexico. Association with biochemical and hematological parameters. Ann Genet 47 (2004) 155-162
133. Lopes C., Dina C., Durand E., and Froguel P. PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologia 46 (2003) 1284-1290
134. Hoffstedt J., Andersson I.L., Persson L., Isaksson B., and Arner P. The common -675 4G/5G polymorphism in the plasminogen activator inhibitor -1 gene is strongly associated with obesity. Diabetologia 45 (2002) 584-587
135. Cao H., van der Veer E., Ban M.R., Hanley A.J., Zinman B., Harris S.B., et al. Promoter polymorphism in PCK1 (phosphoenolpyruvate carboxykinase gene) associated with Type 2 diabetes mellitus. J Clin Endocrinol Metab 89 (2004) 898-903
136. Muller Y.L., Bogardus C., Pedersen O., and Baier L. A Gly482Ser missense mutation in the peroxisome proliferator-activated receptor gamma coactivator-1 is associated with altered lipid oxidation and early insulin secretion in Pima Indians. Diabetes 52 (2003) 895-898
137. Hara K., Tobe K., Okada T., Kadowaki H., Akanuma Y., Ito C., et al. A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes. Diabetologia 45 (2002) 740-743
138. Ek J., Andersen G., Urhammer S.A., Gaede P.H., Drivsholm T., Borch-Johnsen K., et al. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia 44 (2001) 2220-2226
139. Hansen L., Zethelius B., Berglund L., Reneland R., Hansen T., Berne C., et al. In vitro and in vivo studies of a naturally occurring variant of the human p85alpha regulatory subunit of the phosphoinositide 3-kinase: inhibition of protein kinase B and relationships with Type 2 diabetes, insulin secretion, glucose disappearance constant, and insulin sensitivity. Diabetes 50 (2001) 690-693
140. Fanella S., Harris S.B., Young T.K., Hanley A.J., Zinman B., Connelly P.W., et al. Association between PON1 L/M55 polymorphism and plasma lipoproteins in two Canadian aboriginal populations. Clin Chem Lab Med 38 (2000) 413-420
141. Kao W.H., Coresh J., Shuldiner A.R., Boerwinkle E., Bray M.S., and Brancati F.L. Pro12Ala of the peroxisome proliferator-activated receptor-gamma2 gene is associated with lower serum insulin levels in non-obese African Americans: the Atherosclerosis Risk in Communities Study. Diabetes 52 (2003) 1568-1572
142. Doney A., Fischer B., Frew D., Cumming A., Flavell D.M., World M., et al. Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet 3 (2002) 21
143. Doney A.S., Fischer B., Cecil J.E., Boylan K., McGuigan F.E., Ralston S.H., et al. Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia 47 (2004) 555-558
144. Permana P.A., and Mott D.M. Genetic analysis of human Type 1 protein phosphatase inhibitor 2 in insulin-resistant Pima Indians. Genomics 41 (1997) 110-114
145. Xia J., Scherer S.W., Cohen P.T., Majer M., Xi T., Norman R.A., et al. A common variant in PPP1R3 associated with insulin resistance and Type 2 diabetes. Diabetes 47 (1998) 1519-1524
146. Wang H., Chu W., Das S.K., Zheng Z., Hasstedt S.J., and Elbein S.C. Molecular screening and association studies of retinoid-related orphan receptor gamma (RORC): a positional and functional candidate for Type 2 diabetes. Mol Genet Metab 79 (2003) 176-182
147. Garvey W.T., Maianu L., Kennedy A., Wallace P., Ganaway E., Hamacher L.L., et al. Muscle Rad expression and human metabolism: potential role of the novel Ras-related GTPase in energy expenditure and body composition. Diabetes 46 (1997) 444-450
148. Grant S.F., Thorleifsson G., Reynisdottir I., Benediktsson R., Manolescu A., Sainz J., et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of Type 2 diabetes. Nat Genet 38 (2006) 320-323
149. Sesti G., Cardellini M., Marini M.A., Frontoni S., D'Adamo M., and Del Guerra S. A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects. Diabetes 52 (2003) 1280-1283
150. Le Fur S., Le Stunff C., Dos Santos C., and Bougneres P. The common -866 G/A polymorphism in the promoter of uncoupling protein 2 is associated with increased carbohydrate and decreased lipid oxidation in juvenile obesity. Diabetes 53 (2004) 235-239
151. D'Adamo M., Perego L., Cardellini M., Marini M.A., Frontoni S., Andreozzi F., et al. The -866A/A genotype in the promoter of the human uncoupling protein 2 gene is associated with insulin resistance and increased risk of Type 2 diabetes. Diabetes 53 (2004) 1905-1910